Molecular Mechanisms Triggered by Low-calcium Diets
Overview
Authors
Affiliations
Ca is not only essential for bone mineralisation, but also for regulation of extracellular and intracellular processes. When the Ca2+ intake is low, the efficiency of intestinal Ca2+ absorption and renal Ca2+ reabsorption is increased. This adaptive mechanism involves calcitriol enhancement via parathyroid hormone stimulation. Bone is also highly affected. Low Ca2+ intake is considered a risk factor for osteoporosis. Patients with renal lithiasis may be at higher risk of recurrence of stone formation when they have low Ca2+ intake. The role of dietary Ca2+ on the regulation of lipid metabolism and lipogenic genes in adipocytes might explain an inverse relationship between dairy intake and BMI. Dietary Ca2+ restriction produces impairment of the adipocyte apoptosis and dysregulation of glucocorticosteroid metabolism in the adipose tissue. An inverse relationship between hypertension and a low-Ca2+ diet has been described. Ca2+ facilitates weight loss and stimulates insulin sensitivity, which contributes to the decrease in the blood pressure. There is also evidence that dietary Ca2+ is associated with colorectal cancer. Dietary Ca2+ could alter the ratio of faecal bile acids, reducing the cytotoxicity of faecal water, or it could activate Ca2+-sensing receptors, triggering intracellular signalling pathways. Also it could bind luminal antigens, transporting them into mucosal mononuclear cells as a mechanism of immunosurveillance and promotion of tolerance. Data relative to nutritional Ca2+ and incidences of other human cancers are controversial. Health professionals should be aware of these nutritional complications and reinforce the dairy intakes to ensure the recommended Ca2+ requirements and prevent diseases.
Calcium supplementation for people with overweight or obesity.
Cormick G, Ciapponi A, Harbron J, Perez S, Vazquez P, Rivo J Cochrane Database Syst Rev. 2024; 5:CD012268.
PMID: 38721870 PMC: 11079972. DOI: 10.1002/14651858.CD012268.pub2.
Meng J, Wang Y, Cao J, Teng W, Wang J, Zhang Y Foods. 2024; 13(2).
PMID: 38254528 PMC: 10815076. DOI: 10.3390/foods13020227.
Boswald L, Matzek D, Popper B Sci Rep. 2024; 14(1):1791.
PMID: 38245611 PMC: 10799863. DOI: 10.1038/s41598-024-52271-5.
Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?.
Tayal R, Yasmin S, Chauhan S, Singh T, Saini M, Shorog E Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895858 PMC: 10609986. DOI: 10.3390/ph16101387.
Joshi A, Kaur S, Taneja S, Mandal R Biol Trace Elem Res. 2023; 202(4):1477-1502.
PMID: 37523058 DOI: 10.1007/s12011-023-03784-z.